We returned to San Francisco, California for a State of the Science Summit on Breast Cancer. The meeting covered the use of CDK4/6 inhibitors in metastatic hormone receptor-positive breast cancer, adjuvant and neoadjuvant HER2-targeted therapy in early-stage HER2-positive disease, immunotherapy in triple-negative disease, and more.